How did Entero Healthcare perform in FY26?

The company grew its consolidated revenue by 29.6% to ₹6,591 crore and its profit after tax by 35.6% to ₹146 crore.

What is the scale of the new acquisition?

Entero is buying two surgical distribution firms for up to ₹9.21 crore. This is immaterial compared to the company's annual revenue of ₹6,591 crore and market cap of ₹5,887 crore.

Are there any other material updates in this filing?

No. Other items such as director reappointments and ESOP grants are routine and lack price-sensitive impact.

Earnings · Trading · Mid cap

Entero Healthcare reports 30% revenue growth in FY26

The company posted FY26 revenue of ₹6,591 crore and profit of ₹146 crore, alongside a minor bolt-on acquisition.

— 3 earlier stories on Entero Healthcare Solutions Ltd. →

ENTERO By Tipsheet Editorial 25 May 2026 · 9:26 PM IST Verify on BSE · NSE

Mkt cap₹5,127 cr

P/E44.56×

ROE5.50%

Debt / eq.0.17

₹6,591 cr Consolidated revenue for FY26, a 29.6% increase.

What's new

FY26 revenue climbed 29.6% to ₹6,591 crore.
Profit after tax rose 35.6% to ₹146 crore.
The board approved the acquisition of two surgical distribution firms for ₹9.21 crore.

Why this matters

These results track with the company's established growth trajectory. The acquisition of two surgical distribution firms is immaterial relative to the company's ₹5,887 crore market cap.

What we're watching

Whether the company maintains this growth pace in FY27.
Integration progress of the newly acquired distribution assets.
Future capital allocation beyond small bolt-on deals.

The full read

Entero Healthcare delivered 29.6% revenue growth in FY26, reaching ₹6,591 crore. Profit after tax grew 35.6% to ₹146 crore.

These results align with the company's existing trajectory and offer no surprises for the market. Alongside the financial release, the board approved the acquisition of two surgical distribution firms for a total consideration of up to ₹9.21 crore. Given the company's ₹5,887 crore market capitalization, this deal is immaterial.

Routine.

Other board outcomes, including director reappointments and ESOP grants, are purely procedural. The filing confirms the company's current scale but introduces no new tradeable information for investors to digest.

Questions answered

How did Entero Healthcare perform in FY26?: The company grew its consolidated revenue by 29.6% to ₹6,591 crore and its profit after tax by 35.6% to ₹146 crore.
What is the scale of the new acquisition?: Entero is buying two surgical distribution firms for up to ₹9.21 crore. This is immaterial compared to the company's annual revenue of ₹6,591 crore and market cap of ₹5,887 crore.
Are there any other material updates in this filing?: No. Other items such as director reappointments and ESOP grants are routine and lack price-sensitive impact.

Mentioned: Entero Healthcare Solutions Ltd. · ₹6,591 cr FY26 revenue · ₹9.21 cr acquisition

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Entero Healthcare Solutions Ltd.

Miscellaneous

₹5,892 cr

P/E 52.27×

Latest quarter · Dec 2025

Sales₹1,707 cr

Net profit₹34 cr

Op. margin+4.0%

EPS₹6.35

Strength & growth

Debt / equity0.17×

Current ratio2.46×

Story so far

All notes on ENTERO →

25 May 2026 · 9:26 PM IST Entero Healthcare reports 30% revenue growth in FY26
46d ago Entero Healthcare cuts GLP-1 market share estimate by half
47d ago Entero Healthcare revenue grows 29.6% to ₹6,591 crore in FY26
47d ago Entero Healthcare grows revenue 29.6% to ₹6,591 crore in FY26